March 10 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO :
* Valeant receives lender consent for refinancing and amendment of credit agreement
* Valeant - obtained requisite lender approval for previously announced amendment of company's existing credit agreement
* Valeant - credit agreement amendment is expected to become effective concurrently with funding of new term b loans on or about March 21, 2017
* Valeant - obtained requisite lender approval for amendment of existing credit agreement to facilitate borrowing of new term b loans that mature in 2022 Source text for Eikon: ID:nCNWwCC7na Further company coverage: VRX.TO